Evelo Biosciences Stock Forecast, Price & News

Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

Is Evelo Biosciences a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Evelo Biosciences stock.
View analyst ratings for Evelo Biosciences or view top-rated stocks.

How has Evelo Biosciences' stock price been impacted by Coronavirus?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EVLO stock has increased by 4.1% and is now trading at $4.55.
View which stocks have been most impacted by COVID-19.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Evelo Biosciences.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) issued its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.09. During the same quarter in the previous year, the business earned ($0.45) EPS.
View Evelo Biosciences' earnings history.

What price target have analysts set for EVLO?

6 brokerages have issued 1-year price targets for Evelo Biosciences' stock. Their forecasts range from $12.00 to $41.50. On average, they expect Evelo Biosciences' stock price to reach $21.92 in the next twelve months. This suggests a possible upside of 381.7% from the stock's current price.
View analysts' price targets for Evelo Biosciences or view top-rated stocks among Wall Street analysts.

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:

• Simba Gill, President, Chief Executive Officer & Director
• Luca Scavo, Chief Financial Officer, Treasurer & Senior VP
• Mark W. Bodmer, Chief Scientific Officer, President-R&D
• Andrea Itano, Senior Vice President & Head-Research
• Duncan McHale, Chief Medical Officer

Who are some of Evelo Biosciences' key competitors?

Some companies that are related to Evelo Biosciences include Madrigal Pharmaceuticals (MDGL), Rani Therapeutics (RANI), BELLUS Health (BLUSF), Merus (MRUS), Organogenesis (ORGO), Reata Pharmaceuticals (RETA), Revance Therapeutics (RVNC), MannKind (MNKD), Day One Biopharmaceuticals (DAWN), AnaptysBio (ANAB), Kura Oncology (KURA), Northwest Biotherapeutics (NWBO), Crinetics Pharmaceuticals (CRNX), Centessa Pharmaceuticals (CNTA) and ADVANZ PHARMA (CXRXF).
View all of EVLO's competitors.

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Belvedere Trading LLC (0.45%), AE Wealth Management LLC (0.04%) and Cutler Group LP (0.00%). Company insiders that own Evelo Biosciences stock include David R Epstein, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends for Evelo Biosciences.

Which major investors are selling Evelo Biosciences stock?

EVLO stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Evelo Biosciences or view top insider-selling stocks.

Which major investors are buying Evelo Biosciences stock?

EVLO stock was bought by a variety of institutional investors in the last quarter, including Belvedere Trading LLC, and AE Wealth Management LLC. Company insiders that have bought Evelo Biosciences stock in the last two years include David R Epstein, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Evelo Biosciences or or view top insider-buying stocks.

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $4.55.

How much money does Evelo Biosciences make?

Evelo Biosciences has a market capitalization of $243.24 million. The company earns $-93.67 million in net income (profit) each year or ($2.39) on an earnings per share basis.

How many employees does Evelo Biosciences have?

Evelo Biosciences employs 2,018 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

Where are Evelo Biosciences' headquarters?

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at (617) 577-0300 or via email at [email protected].